latest news releases from the newsroom
Market Pulse Announces its Hot Stock Alerts for Thursday, January 27, 2005: XCHC, MRK, XOM, MBEU
ATLANTA, Jan. 27, 2005 (PRIMEZONE) -- Market Pulse is pleased to introduce our featured stock, The X-Change Corporation (OTCBB:XCHC), to the investment community! X- Change is new to Market Pulse and is a company that was organized to seek merger or acquisition candidates in the oil and gas industry! XCHC just had excellent news out before today's opening bell regarding the plans to step up production on their fourth east Texas oil well! Investors should be watching this one closely! Other notable stocks that look great lately from a fundamental and technical perspective include:
Capital Research Group, Inc
Early Stock Market Alerts for Thursday, January 27, 2005: OBDP, ADCT, CSCO, AMD
WESTON, Fla., Jan. 27, 2005 (PRIMEZONE) -- TheSUBWAY.com names the following stocks to its Stock Alerts List: Orbit Drop Inc. (Pink Sheets:OBDP), ADC Telecommunications (Nasdaq:ADCT), Cisco Systems Inc. (Nasdaq:CSCO), Advanced Micro Devices Inc. (NYSE:AMD).
Ocwen Financial Corp.
Ocwen Financial Corporation Announces Fourth Quarter and 2004 Net Income
WEST PALM BEACH, Fla., Jan. 27, 2005 (PRIMEZONE) -- Ocwen Financial Corporation (NYSE:OCN) today reported net income for the fourth quarter of 2004 of $4.1 million or $0.07 per share compared to net income of $4.5 million or $0.07 per share for the fourth quarter of 2003. For the year ended December 31, 2004 the Company reported net income of $59.2 million or $0.90 per share as compared to $4.8 million or $0.07 per share in the same period in 2003. Net income for 2004 includes a net tax benefit of $30.8 million, primarily reflecting the partial reversal of the deferred tax asset valuation allowance that was established in prior years. Pre-tax income in 2004 was $28.2 million as compared to $5.0 million last year.
Vitrolife Receives Product Approval in USA
STOCKHOLM, Sweden, Jan. 27, 2005 (PRIMEZONE) -- Vitrolife has received sales approval from the Food and Drug Administration (FDA) to start marketing of its product ICSI(TM). The product is the first of its kind that contains synthetically manufactured albumin instead of albumin purified from blood, which increases safety and simplifies handling. ICSI stands for intracytoplasmatic sperm injection and is a technology for the treatment of male infertility. This is one of the most rapidly growing segments within assisted fertilization. "Our new ICSI product is a good example of our ability to develop the safest and most effective products within the treatment of infertility," says Magnus Nilsson, Vitrolife's CEO.